Ensysce Biosciences
ENSC
10 hedge funds and large institutions have $237K invested in Ensysce Biosciences in 2024 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 1 closing their positions.
319% more capital invested
Capital invested by funds: $56.4K → $237K (+$180K)
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
25% more funds holding
Funds holding: 8 → 10 (+2)
0.52% more ownership
Funds ownership: 0.11% → 0.63% (+0.52%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$244K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$13.3K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.16K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.97K |
| 5 |
MSG
Main Street Group
Glen Allen,
Virginia
|
+$397 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$413 |
| 2 |
ASN
Advisory Services Network
Atlanta,
Georgia
|
-$368 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SM
1
Sabby Management
Miami Beach,
Florida
| $182K | +$244K | +15,370 | New |
|
|
2
Geode Capital Management
Boston,
Massachusetts
| $14.5K | +$2.16K | +136 | +13% |
|
3
Vanguard Group
Malvern,
Pennsylvania
| $14.4K | – | – | – |
|
|
4
UBS Group
Zurich,
Switzerland
| $9.96K | +$13.3K | +841 | New |
|
|
5
Renaissance Technologies
New York
| $8K | -$413 | -26 | -4% |
|
|
TRCT
6
Tower Research Capital (TRC)
New York
| $6.45K | +$1.97K | +124 | +30% |
|
7
BlackRock
New York
| $770 | – | – | – |
|
|
MSG
8
Main Street Group
Glen Allen,
Virginia
| $289 | +$397 | +25 | New |
|
9
Wells Fargo
San Francisco,
California
| $20 | – | – | – |
|
|
PMFA
10
Plante Moran Financial Advisors
Southfield,
Michigan
| $16 | – | – | – |
|
|
ASN
11
Advisory Services Network
Atlanta,
Georgia
| – | -$368 | -23 | Closed |
|
ENSC Hedge Fund Activity: Q1 2024 in Review
10 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Ensysce Biosciences (ENSC) for Q1 2024, worth a combined $237K — up 319% from $56.4K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new ENSC positions and 1 closed out — a net gain of 2 holders — while 2 added to existing stakes and 1 trimmed.
The largest buyer was Sabby Management, opening a new position worth an estimated $244K. The largest seller was Renaissance Technologies, cutting an estimated $413.
- 10 institutional investors held Ensysce Biosciences (ENSC) as of Q1 2024, up from 8 in Q4 2023.
- Funds reported $237K of Ensysce Biosciences stock for Q1 2024, up 319% quarter-over-quarter.
- 3 funds opened new Ensysce Biosciences positions in Q1 2024 and 1 closed out, a net change of +2 holders.
- The largest Ensysce Biosciences buyer in Q1 2024 was Sabby Management, an estimated $244K added.
- The largest Ensysce Biosciences seller in Q1 2024 was Renaissance Technologies, an estimated $413 sold.
Based on aggregated 13F filings for Q1 2024.